Astrazeneca Plc (AZN) upgraded to Buy by UBS
UBS rated Buy Astrazeneca Plc (NYSE: AZN) on 04/27/2009, when the stock price was $36.19. Since
then, Astrazeneca Plc has gained 90.22% as of 04/13/2015's recent price of $68.84. If you would have followed this UBS's recommendation on AZN, you would have gained 90.21% of your investment in 2177 days.
AstraZeneca PLC (AstraZeneca) is engaged in the discovery, development, manufacturing and marketing of prescription pharmaceuticals and biological products for important areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. The Company?s product portfolio comprise: Arimidex, Crestor, Nexium, Seroquel and Symbicort. It has operations in various markets, such as China, United Kingdom, Sweden and the United States. It has 26 manufacturing sites in 18 countries. Cardiovascular product pipeline includes Saxagliptin, Dapagliflozin, Atherosclerosis/dyslipidaemia, Thrombosis and Atrial fibrillation. Gastrointestinal pipeline includes life cycle management initiatives. AstraZeneca?s Infection pipeline MedImmune and Dedicated tuberculosis (TB) research. Oncology product pipeline includes Zactima (vandetanib), Zactima (vandetanib), ZD4054 and MedImmune.
is the leading global wealth manager, a top tier investment banking and securities firm, and one of the largest global asset managers.
In Switzerland, UBS
is the market leader in retail and commercial banking.
With headquarters in Zurich and Basel, Switzerland, UBS
operates in over 50 countries and from all major international centers.
employs more than 80,000 people.